Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsLTS:0RKT 66 Cyclically Adjusted PS Ratio is 6.53 as of Jul. 27, 2026, which is 55% below its 10-year median of 14.57. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł92.63. The stock has 3 warning signs investors should review. Among 537 Biotechnology companies, Ryvu Therapeutics ranks better than 56.98% on this metric.
The historical rank and industry rank for Ryvu Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
LTS:0RKT'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4 Med: 14.57 Max: 23.68
Current: 4.33
During the past years, Ryvu Therapeutics's highest Cyclically Adjusted PS Ratio was 23.68. The lowest was 4.00. And the median was 14.57.
LTS:0RKT's Cyclically Adjusted PS Ratio is ranked better than 56.98% of 537
companies
in the Biotechnology industry
Industry Median: 5.63
vs LTS:0RKT: 4.33
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Ryvu Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2026 was zł0.733. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is zł4.63 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Ryvu Therapeutics (LTS:0RKT) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Ryvu Therapeutics Cyclically Adjusted PS Ratio Related Terms
Ryvu Therapeutics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics Cyclically Adjusted PS Ratio Chart
LTS:0RKT vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Cyclically Adjusted PS Ratio falls into.
Ryvu Therapeutics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Ryvu Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 6.53 mean?
Ryvu Therapeutics (LTS:0RKT) has a Cyclically Adjusted PS Ratio of 6.53 as of Jul. 27, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors. This is 55% below median its historical median of 14.57. Over the past decade, Ryvu Therapeutics' Cyclically Adjusted PS Ratio has ranged from 4.00 to 23.68. According to the industry distribution chart, Ryvu Therapeutics ranks #231 out of 537 companies in the Biotechnology industry, placing it in the top 43%.
Is Ryvu Therapeutics' Cyclically Adjusted PS Ratio too high?
Ryvu Therapeutics' current Cyclically Adjusted PS Ratio of 6.53 is 55% below median its 10-year median of 14.57. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 23.68. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.63. Ryvu Therapeutics' value of 6.53 is 16% above this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #231 out of 537 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #231 out of 537 companies for Cyclically Adjusted PS Ratio. This puts Ryvu Therapeutics in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.63. Ryvu Therapeutics' value of 6.53 is 16% above this benchmark. Historically, Ryvu Therapeutics' own Cyclically Adjusted PS Ratio has ranged from 4.00 to 23.68 over the past decade. While the company's 10-year median is 14.57 vs. the industry median of 5.63, Ryvu Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.63, based on 537 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current Cyclically Adjusted PS Ratio of 6.53 is 16% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Cyclically Adjusted PS Ratio is 6.53, which is 55% below median its own 10-year median of 14.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current Cyclically Adjusted PS Ratio of 6.53. The stock's GF Value™ is zł92.63, compared to a current price of zł30.25 — trading 67.3% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 6.53, which is 55% below median its 10-year median of 14.57 and 16% above the Biotechnology industry median of 5.63. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current Cyclically Adjusted PS Ratio is 6.53 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł30.25 is trading 67.3% below its estimated GF Value™ of zł92.63.
Key valuation signals for LTS:0RKT:
Cyclically Adjusted PS Ratio: 6.53 (55% below median its 10-year median of 14.57)
GF Value™: zł92.63 vs. price of zł30.25 (67.3% below fair value)
Industry Position: 16% above the Biotechnology median (#231 of 537)
No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for LTS:0RKT
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKT has been successfully added to your 
